u/britta_boateng

no names without evidence, that is the sidebar rule and it is a good one

What is the actual question underneath the question? Happy to answer both.

a COA is a certificate of analysis, the lab document for a batch

Wrote the concentration on the vial after reading it here. Have never once had to reconstruct it from memory since.

week two with nothing happening is normal

A series across separate lots estimates a process. Repeat tests on one lot estimate the measurement. Both are useful and they answer different questions.

Is that the same lot as the one in the thread from last month?

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

the lane is the unit of analysis, not the supplier

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

Has appetite changed yet, independent of the scale?

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

bacteriostatic water has a preservative, sterile water does not

The habits are what carried it for a while.

piotr_bruun is right that regain is a documented outcome rather than a character verdict.

With a week-long half-life, exposure declines over several weeks after the last dose rather than stopping with it. The lag is why the first fortnight is uninformative.

Inter-lab variance on this assay runs roughly a point either way, driven mostly by gradient and integration. Two results inside that band agree; they do not disagree quietly.

SELECT was cardiovascular outcomes, not weight

private script pricing varies by pharmacy here too

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Correction: that was clearance time, not carrier time. The lane table separates them for exactly this reason.

Correcting myself: I quoted net peptide content against somebody else’s area percent. Not a comparison.

That service reports area percent by default. Worth stating, since the thread has been comparing it to a mass figure.

Small fix — the name you are describing is in the wider-market table with almost nothing on file, not in the documented twenty.

That is a report count, not a test count, and it changes how thin the evidence base actually is.

Has anyone else in the thread got the same domain in their history?

regain is the expected outcome and framing it as failure helps nobody

Right, and the last mile is where my variance has always come from, not the international leg.

What is the actual question underneath the question? Happy to answer both.

Date of analysis anchors the result to a manufacturing period. A two-year-old result is evidence about two years ago and should be read that way.

Correcting myself: the compounded position changed and my earlier comment was describing the old one.

Compounded supply arrangements have changed materially in recent years. Advice predating that change describes a situation that no longer applies.

ask the dumb question, three other people are searching for it

What was the claim on the certificate you are comparing against?

I would not read a single slow shipment as a lane change. Post it and let the median move if it is real.

Yes — nobody here is your clinician, and the good answers on this board all end with that.

no tracking numbers, ever